Article Text

Download PDFPDF
Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing
  1. S A Morré1,
  2. R Welte2,
  3. M J Postma3
  1. 1Vrije Universiteit Medical Center, Laboratory of Immunogenetics, Amsterdam, Netherlands
  2. 2National Institute for Public Health and the Environment, Center for Health Services Research, Bilthoven, Netherlands
  3. 3Groningen University Institute for Drug Exploration/University of Groningen Research Institute of Pharmacy (GUIDE/GRIP), Groningen, Netherlands
  1. Correspondence to:
 Dr Postma;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Screening of asymptomatic Chlamydia trachomatis (CT) infections is indicated to prevent the spread of CT and the development of secondary complications like pelvic inflammatory disease, ectopic pregnancy, and tubal infertility. Cost effectiveness presents an important aspect in the decision making regarding actual implementation. A recent paper in this journal by Van Valkengoed et al1 addressed cost effectiveness, using an established pharmacoeconomic model,2 of a systematic screening programme for asymptomatic CT infections in women registered in general practices in Amsterdam, based on mailed home obtained urine specimens.3 The aim of this letter is to extend the application of the pharmacoeconomic model with regard to pooling and improved …

View Full Text